EUVIMEDEUVIMED entdecken
Open Access

Additive Effects of Dorzagliatin and Glucagon-Like Peptide 1 Receptor Agonism in a Novel Mouse Model of GCK -MODY and in Obese db/db Mice

Shadai Salazar, Luis Fernando Delgadillo-Silva, Priscila Carapeto, Mohamed Mourad Kenfaoui, Karen Dakessian, Rana Melhem, Audrey Provencher-Girard, Giada Ostinelli, Julie Turgeon, Imane Kaci, Francis Migneault, Mark O Huising und 3 weitere

Diabetes · 2026

DOI: 10.2337/db25-0520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2026. Verfasst von Shadai Salazar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of the Hospital Center of the University of Montreal and University of Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucokinase, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Wellcome Trust, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucokinase (GK) catalyzes the key regulatory step in glucose-stimulated insulin secretion (GSIS). Correspondingly, hetero- and homozygous mutations in human GCK cause maturity-onset diabetes of the young (GCK-MODY) and permanent neonatal diabetes mellitus, respectively. To explore the possible utility of GK activators (GKAs) and of glucagon-like peptide 1 (GLP-1) receptor agonists in these diseases, we have developed a novel hypomorphic Gck allele in mice encoding an aberrantly spliced mRNA. In islets from homozygous knock-in (GckKI/KI) mice, GK immunoreactivity was reduced by >85%, and GSIS eliminated. Homozygous GckKI/KI mice displayed frank diabetes (fasting blood glucose >18 mmol/L; HbA1c ∼108 mmol/mol), ketosis, and nephropathy. Heterozygous GckKI/+ mice were glucose intolerant (HbA1c ∼37 mmol/mol). Abnormal glucose-stimulated Ca2+ dynamics in GckKI/+ islets were completely reversed by the GKA dorzagliatin, which was largely inactive in homozygous GckKI/KI mouse islets. The GLP-1 receptor agonist exendin-4 improved glucose tolerance in male GckKI/+ mice, an action potentiated by dorzagliatin. Sex-dependent additive effects of these agents were also observed on insulin secretion in vitro. Similar additive effects of the drugs were observed in obese hyperglycemic db/db mice. Combined treatment with GKA and incretin mimetics may thus be useful in GCK-MODY and in more common forms of type 2 diabetes. Article Highlights Glucokinase (GK) deficiency can drive maturity-onset diabetes of the young (GCK-MODY) in heterozygotes and permanent neonatal diabetes in homozygotes. We describe a hypomorphic Gck allele that results in aberrant splicing in islets and liver lowering GK activity by ∼85%. Whereas heterozygous mutant mice are mildly hyperglycemic, homozygotes have frank diabetes but survive to adulthood. Dorzagliatin potentiates the effects of glucagon–like receptor-1 receptor activation sex dependently in heterozygous Gck mice and in obese hyperglycemic db/db mice. Combined use of these drugs may be useful in some forms of GCK-MODY and in obesity-related type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2GlucokinaseGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsAnimalsMiceDisease Models, AnimalMaleIslets of LangerhansGlucagon-Like Peptide-1 ReceptorInsulin SecretionFemale

Substanzen

GlucokinaseGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorHypoglycemic Agents

Autor:innen und Institutionen

  • Research Center of the Hospital Center of the University of Montreal and University of Montreal, Quebec, Canada.
  • Department of Biochemistry and Molecular Medicine, Université de Montréal, Quebec, Canada.
  • Département de Médecine, Université de Montréal, Montréal, Quebec, Canada.
  • Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, Quebec, Canada.
  • Department of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California, Davis, Davis, CA.
  • Department of Physiology and Membrane Biology, School of Medicine, University of California, Davis, Davis, CA.

ORCID-Profile: Guy A Rutter

Förderung

  • CIHR
  • Wellcome Trust
  • NIDDK NIH HHS
  • CIHR-JDRF Team
  • NIH-NIDDK
  • Diabetes UK
  • Fonds de Recherche du Qubec - Nature, Science
  • MRC Programme

Zitieren

APA

Salazar, S., Delgadillo-Silva, L. F., Carapeto, P., Kenfaoui, M. M., Dakessian, K., Melhem, R., Provencher-Girard, A., Ostinelli, G., Turgeon, J., Kaci, I., Migneault, F., Huising, M. O., Hébert, M. J., Chaker-Margot, M., & Rutter, G. A. (2026). Additive Effects of Dorzagliatin and Glucagon-Like Peptide 1 Receptor Agonism in a Novel Mouse Model of GCK -MODY and in Obese db/db Mice. Diabetes. https://doi.org/10.2337/db25-0520

Vancouver

Salazar S, Delgadillo-Silva LF, Carapeto P, Kenfaoui MM, Dakessian K, Melhem R, et al. Additive Effects of Dorzagliatin and Glucagon-Like Peptide 1 Receptor Agonism in a Novel Mouse Model of GCK -MODY and in Obese db/db Mice. Diabetes. 2026. doi:10.2337/db25-0520

BibTeX
@article{Salazar2026,
  author = {Salazar, Shadai and Delgadillo-Silva, Luis Fernando and Carapeto, Priscila and Kenfaoui, Mohamed Mourad and Dakessian, Karen and Melhem, Rana and Provencher-Girard, Audrey and Ostinelli, Giada and Turgeon, Julie and Kaci, Imane and Migneault, Francis and Huising, Mark O and Hébert, Marie-Josée and Chaker-Margot, Malik and Rutter, Guy A},
  title = {Additive Effects of Dorzagliatin and Glucagon-Like Peptide 1 Receptor Agonism in a Novel Mouse Model of GCK -MODY and in Obese db/db Mice},
  journal = {Diabetes},
  year = {2026},
  doi = {10.2337/db25-0520}
}
Kostenlos starten →